{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:10:50Z","timestamp":1790993450983,"version":"4.1.0"},"reference-count":55,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ITT"],"DOI":"10.2147\/itt.s577653","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T12:05:12Z","timestamp":1770725112000},"page":"1-11","source":"Crossref","is-referenced-by-count":3,"title":["Recent Advances in Vitiligo Treatment"],"prefix":"10.2147","volume":"Volume 15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6052-5953","authenticated-orcid":true,"given":"Ye","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangxi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingru","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1527-4760","authenticated-orcid":true,"given":"Yurong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3456-160X","authenticated-orcid":true,"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"21852195","DOI":"10.1111\/jdv.19450","volume":"37","author":"Seneschal","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"621648","DOI":"10.1146\/annurevimmunol100919023531","volume":"38","author":"Frisoli","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1038\/s41467-019-09963-8","volume":"10","author":"Tulic","year":"2019","journal-title":"Nat Commun"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"769778","DOI":"10.1016\/j.jid.2018.10.032","volume":"139","author":"Richmond","year":"2019","journal-title":"J Invest Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jid.2023.08.006","volume":"144","author":"Lee","year":"2024","journal-title":"J Invest Dermatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1468-3083.2006.02101.x","volume":"21","author":"Fai","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"8692","DOI":"10.1016\/j.jdermsci.2023.12.008","volume":"113","author":"Inoue","year":"2024","journal-title":"J Dermatol Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"790125","DOI":"10.3389\/fimmu.2021.790125","volume":"12","author":"Qi","year":"2021","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"110120","DOI":"10.1016\/S0140-6736(20)30609-7","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N Engl J Med"},{"key":"ref12","unstructured":"A study to evaluate the efficacy and safety of ruxolitinib cream with phototherapy in participants with vitiligo.ClinicalTrials.gov identifier: NCT05247489. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05247489. Accessed October 13, 2025."},{"key":"ref13","unstructured":"A study to assess the safety and efficacy of ruxolitinib cream in participants with genital vitiligo. ClinicalTrials.gov identifier: NCT05750823.July 11, 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05750823. Accessed October 13, 2025."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.2147\/JIR.S356316","volume":"15","author":"Zhang","year":"2022","journal-title":"J Inflamm Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"15593258221105370","DOI":"10.1177\/15593258221105370","volume":"20","author":"Dong","year":"2022","journal-title":"Dose Response"},{"key":"ref16","unstructured":"A study of the effect and tolerance of the association of baricitinib and phototherapy versus phototherapy in adults with progressive vitiligo (BARVIT). ClinicalTrials.gov identifier: NCT04822584. June 13, 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04822584. Accessed October 13, 2025."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jamadermatol.2024.5737","volume":"161","author":"Seneschal","year":"2025","journal-title":"JAMA Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"503","DOI":"10.4103\/idoj.IDOJ_474_18","volume":"10","author":"Sonthalia","year":"2019","journal-title":"Indian Dermatol Online J"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"102655","DOI":"10.1016\/j.eclinm.2025.103167","author":"Passeron","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref20","unstructured":"A study to assess adverse events and effectiveness of upadacitinib oral tablets in adult and adolescent participants with vitiligo (Viti-Up). ClinicalTrials.gov identifier: NCT06118411. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06118411. Accessed October 13, 2025."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2023.04.001","volume":"88","author":"Ezzedine","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"287300","DOI":"10.1016\/j.immuni.2017.01.009","volume":"46","author":"Cheuk","year":"2017","journal-title":"Immunity"},{"key":"ref23","unstructured":"A 52-week study of ritlecitinib oral capsules in adults and adolescents with nonsegmental vitiligo (Active and Stable) Tranquillo (Tranquillo). ClinicalTrials.gov identifier: NCT05583526. July 11, 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05583526. Accessed October 13, 2025."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s40257-021-00627-2","volume":"22","author":"Zhao","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"ref25","unstructured":"A study to assess the efficacy and safety of SHR0302 ointment in adult patients with vitiligo. ClinicalTrials.gov identifier: NCT04774809. 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04774809. Accessed October 13, 2025."},{"key":"ref26","unstructured":"A study of ICP-332 in subjects with non-segmental vitiligo. ClinicalTrials.gov identifier: NCT07047612. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07047612. Accessed October 13, 2025."},{"key":"ref27","unstructured":"A phase II study of the efficacy and safety of VC005 tablets in subjects with non-segmental vitiligo. ClinicalTrials.gov identifier: NCT07172347. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07172347. Accessed October 13, 2025."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1639732","DOI":"10.3389\/fimmu.2025.1639732","volume":"16","author":"Su","year":"2025","journal-title":"Front Immunol"},{"key":"ref29","unstructured":"A study to evaluate AMG 714 for vitiligo (REVEAL). ClinicalTrials.gov identifier: NCT04338581. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04338581. Accessed October 13, 2025."},{"key":"ref30","first-page":"52","volume":"18","author":"Warren","year":"2025","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref31","unstructured":"An open-label pilot study of Abatacept for the treatment of vitiligo. ClinicalTrials.gov identifier: NCT02281058. 2017. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02281058. Accessed October 13, 2025."},{"key":"ref32","unstructured":"A study to compare the efficacy and safety of SCENESSE and narrow-band ultraviolet (NB-UVB) light versus NB-UVB light alone in patients with vitiligoClinicalTrials.gov identifier: NCT06109649. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06109649. Accessed October 13, 2025."},{"key":"ref33","unstructured":"A study of daily topical rapamycin for vitiligo. ClinicalTrials.gov identifier: NCT05342519. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05342519. Accessed October 13, 2025."},{"key":"ref34","unstructured":"A study to evaluate the efficacy and safety of metformin in vitiligo. ClinicalTrials.gov identifier: NCT05607316. 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05607316. Accessed October 13, 2025."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.25259\/JCAS_16_2024","volume":"18","author":"Khalili","year":"2025","journal-title":"J Cutan Aesthet Surg"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"839848","DOI":"10.1111\/jocd.16043","volume":"23","author":"Kim","year":"2024","journal-title":"J Cosmet Dermatol"},{"key":"ref37","unstructured":"A study of the repigmentation of stable vitiligo lesions using Spray-On Skin\u2122 cells (TONE). ClinicalTrials.gov identifier: NCT05971381. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05971381. Accessed October 13, 2025."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1001\/jamadermatol.2017.5795","volume":"154","author":"Razmi","year":"2018","journal-title":"JAMA Dermatol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s00403-025-03813-y","volume":"317","author":"Eleslam Shaker","year":"2025","journal-title":"Arch Dermatol Res"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s00403-024-03045-6","volume":"316","author":"ElGhareeb","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"6365","DOI":"10.25259\/JCAS_144_2024","volume":"18","author":"Kerure","year":"2025","journal-title":"J Cutan Aesthet Surg"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"827835","DOI":"10.2147\/CCID.S315407","volume":"14","author":"Ragab","year":"2021","journal-title":"Clin Cosmet Invest Dermatol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"15391543","DOI":"10.2147\/CCID.S412948","volume":"16","author":"Zhou","year":"2023","journal-title":"Clin Cosmet Invest Dermatol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e13769","DOI":"10.1111\/srt.13769","volume":"30","author":"Gui","year":"2024","journal-title":"Skin Res Technol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"e13226","DOI":"10.1111\/pcmr.13226","volume":"38","author":"Zhang","year":"2025","journal-title":"Pigm Cell Melanoma Res"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1069196","DOI":"10.3389\/fimmu.2022.1069196","volume":"13","author":"He","year":"2022","journal-title":"Front Immunol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"863878","DOI":"10.1111\/bjd.16049","volume":"178","author":"Osinubi","year":"2018","journal-title":"Br J Dermatol"},{"key":"ref48","unstructured":"A study of vitiligo and psychodrama therapy. ClinicalTrials.gov identifier: NCT05991596. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05991596. Accessed October 13, 2025."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"936","DOI":"10.3390\/cells12060936","volume":"12","author":"Chang","year":"2023","journal-title":"Cells"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.3390\/antiox12122082","volume":"12","author":"Speeckaert","year":"2023","journal-title":"Antioxidants"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"e1720","DOI":"10.1002\/ctm2.1720","volume":"14","author":"Huang","year":"2024","journal-title":"Clin Transl Med"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"e14738","DOI":"10.1111\/dth.14738","volume":"34","author":"Salem","year":"2021","journal-title":"Dermatol Ther"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"e2404064","DOI":"10.1002\/advs.202404064","volume":"11","author":"Wang","year":"2024","journal-title":"Adv Sci"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"e14297","DOI":"10.1111\/dth.14297","volume":"33","author":"Salloum","year":"2020","journal-title":"Dermatol Ther"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"125106","DOI":"10.1016\/j.ijpharm.2024.125106","volume":"670","author":"Sahu","year":"2025","journal-title":"Int J Pharm"}],"container-title":["ImmunoTargets and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/111870","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/111870","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T12:05:16Z","timestamp":1770725116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/recent-advances-in-vitiligo-treatment-peer-reviewed-fulltext-article-ITT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":55,"URL":"https:\/\/doi.org\/10.2147\/itt.s577653","relation":{},"ISSN":["2253-1556"],"issn-type":[{"value":"2253-1556","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}